|Bid||3,075.00 x 0|
|Ask||3,085.00 x 0|
|Day's range||2,988.00 - 3,185.00|
|52-week range||2,336.00 - 3,800.00|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||55.56|
|Earnings date||13 May 2021|
|Forward dividend & yield||16.00 (0.45%)|
|Ex-dividend date||29 Sept 2021|
|1y target est||6,388.90|
JCR announced that EMA has granted orphan drug designation to JR-171, an investigational drug for the treatment of Hurler syndrome (MPS 1).
JCR Pharmaceutical announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved IZCARGO for Hunter syndrome, or MPS II.